Entropy Neurodynamics Limited has released a press release.
Study results indicate exosomes safe for clinical pursuit
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- FY2022 Appendix 4E and Annual Report
- EX1 to receive a further $0.48m in prepaid R&D Tax Incentive
- EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim
- Business Update
- Response to ASX Price Query
Later from Entropy Neurodynamics
- Exopharm Received R&D Tax Incentive Refund
- EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive
- Added Funding for 2023
- Appendix 4D and Half Year Report for period 31 December 2022
- EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics